<DOC>
	<DOCNO>NCT02819765</DOCNO>
	<brief_summary>This study aim establish biorepository phenotyping database investigate longitudinal change ALS subject . Blood , include DNA RNA , cerebrospinal fluid ( CSF ) electrophysiologic measure collect every 3 month 1 year . The database specimen repository make available ALS researcher merit basis .</brief_summary>
	<brief_title>Deep Phenotyping Patients With ALS</brief_title>
	<detailed_description>Rationale Study The Northeast ALS Consortium ( NEALS ) biorepository exist resource provide scientist wide range sample associate clinical information . It primarily cross sectional nature ; longitudinal collection associate limited set clinical functional assessment . The investigator goal continue build repository collection protocol propose , associate biofluid collection specific measure upper low motor neuron function . This project compliment others upgrade NEALS biorepository infrastructure , include updating computer system , expand number sample freezer establish repository Western United States , strengthen standard operating procedure repository . The project also support exist effort expand biorepository collect new blood spinal fluid sample people ALS . Study Design This multicenter , non interventional , longitudinal study patient ALS . There four ( 4 ) subject visit study : Baseline , month 6 , month 12 , month 18 . At visit , subject biofluids collect , evaluated assessment tool focus upper low motor neuron burden well cognitive function . Study Objectives Endpoints The primary objective study obtain deep phenotyping information patient study regular interval 18 month , conjunction biofluid collection time period . The secondary objective study integrate data study ongoing project via NEALS biorepository , future collection plan . Endpoints study : - Motor unit number estimation perform bilateral upper extremity muscle use multipoint incremental technique ( MIMUNE ) ; - Vital capacity , measure use slow vital capacity ( SVC ) . - Lower motor neuron excitability assess threshold track nerve conduction study ( ttNCS ) least affected intrinsic hand muscle . - Cognitive abnormality assess use ALS Cognitive Behavior Screen ( ALS-CBS ) ; - Upper motor neuron burden assess use transcranial magnetic stimulation ( TMS ) , employ pair pulse protocol record least affected upper extremity intrinsic hand muscle ; - Hand hold dynamometry ( HHD ) perform 10 muscle group test bilaterally ; - Global function ( ALSFRS-R ) ; - Vital capacity , measure use slow vital capacity ( SVC ) . At visit , blood collect banked biomarker discovery ; CSF collect baseline , month 6 , month 18 . Study Locations Approximately 10-15 Northeast ALS Consortium ( NEALS ) Centers US participate study . Sites perform ttNCS and/or TMS still participate . Number Planned Subjects One hundred fifty ( 150 ) subject study . It estimate 10 15 subject shall enrol per site . Study Population This study conduct subject meet El Escorial criterion possible , laboratory- support probable , probable , definite ALS . Time diagnosis study entry must 24 month less . At screening , eligible subject must least 18 year old must provide write informed consent . Detailed criterion describe full protocol . Duration Study Active assessment period 18 month ; 1-year enrolment period expect .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<criteria>Participants sporadic ALS diagnose possible , laboratorysupported probable , probable definite accord World Federation Neurology El Escorial criterion . First ALS diagnosis occur ≤2 year ( 24 month ) prior Screening Visit . Expected survive &gt; 1 year ( 12 month ) enrollment . Male female , aged 1875 . Ability medically undergo lumbar puncture ( LP ) determine investigator ( i.e. , bleed disorder , allergy local anesthetic , skin infection near LP site , evidence high intracranial pressure ) . Willingness medical ability comply schedule visit , LP CSF collection , laboratory test , study procedure . Ability understand purpose risk study provide sign date informed consent authorization use protect health information ( PHI ) accordance national local subject privacy regulation . Geographic accessibility study site . Any contraindication LP , include limited : Platelet count &lt; 100,000/µL . History bleed disorder . History intolerance LP procedure . Evidence topical skin infection LP site . Prior spinal fusion surgery spinal surgery LP site . History allergy adverse reaction local anesthetic use study . History traumatic central nervous system injury stroke . Other unspecified reason , opinion Investigator , make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>